Meet the people who make Transposagen a leader in genetically modified animal models, cell engineering services, and gene editing tools.
Chief Executive Officer
Dr. Printen has been identifying and commercializing technologies in the life science sector for over 20 years. Most recently, he was Chief Commercial Officer at Cellara, LLC, an early-stage company developing information technologies for stem cell culture. Prior to this, Dr. Printen was with Life Technologies (now ThermoFisher) for 12 years in a variety of roles, from R&D Director to Product Management Director to ultimately Director of New Markets and Business Development, where he was responsible for developing and executing on company growth strategies. Before Life Technologies, Dr. Printen held the position of Associate Director, Enabling Science and Technology, at AstraZeneca Pharmaceuticals, (UK) where he was focused on identifying and implementing new technologies to improve the drug discovery process. Dr. Printen has also been involved with a number of professional societies, including board member of BioForward, the Wisconsin BIO affiliate, and the Society of Biomolecular Screening, where he served as president. In addition, he has also served as a consultant with programs helping to bring academic discoveries to market, such as the Discovery2Product program and the WARF Accelerator program at the University of Wisconsin. Dr. Printen did his post-doctoral work at Parke-Davis (Ann Arbor), holds a doctoral degree from the Institute of Molecular Biology at the University of Oregon and is the author of 19 scientific papers and patents.
Director, Cell Line Engineering Division
Dr. Allison’s 15+ year career in life sciences product development began with a position at Sigma-Aldrich, where he initially led an R&D team in the development of cell culture products for both pluripotent and adult stem cells. Later, he was part of the team responsible for bringing genome editing technology to Sigma and spent several years leading the development of custom engineered cell lines for both stem cell models and other cell-based assays utilizing that technology. Dr. Allison received his undergraduate degree in Biological Sciences from Quincy University in Quincy, Illinois and his Ph.D. in Cell and Structural Biology from the University of Illinois at Urbana-Champaign.
Director, Reagents Division
Ken Miller has over 20 years’ experience in the application of molecular biology to the generation and evaluation of rodent models, imaging reporters, cell lines, and stem cell models to support drug discovery efforts. Prior to joining Transposagen, Ken worked for 14 years at Pfizer, Inc. in the genetically modified models group where he constructed a large number of mouse models for multiple therapeutic indications, as well as supported genetic modification and genome editing in human ESC and iPSC models. Before his time at Pfizer, Ken worked in the Immunology Department at Schering-Plough Research Institute (now Merck, Inc.) providing molecular biology support for assay development, protein production, and target identification. Ken holds an M.S. degree in Molecular Biology from the University of Illinois, Department of Microbiology.